Noris, Marina
Donadelli, Roberta
Remuzzi, Giuseppe
Article History
Received: 8 February 2018
Revised: 8 May 2018
Accepted: 25 May 2018
First Online: 9 June 2018
Compliance with ethical standards
:
: Marina Noris has received honoraria from Alexion Pharmaceuticals for giving lectures and participating in advisory boards. None of these activities have had any influence on the results or interpretation in this article. GR has consultancy agreements with AbbVie*, Alexion Pharmaceuticals*, Bayer Healthcare*, Reata Pharmaceuticals*, Novartis Pharma*, AstraZeneca*, Otsuka Pharmaceutical Europe* and Concert Pharmaceuticals*.*No personal remuneration is accepted, and compensations are paid to his institution for research and educational activities. The other authors declare no conflict of interest.